Clinical value of serum cardiac troponin I in patients with type 2 diabetes mellitus and coronary heart disease

Abstract

Objective To investigate the value of serum cardiac troponin I (cTnI) in the diagnosis and treatment of patients with type 2 diabetes mellitus and coronary heart disease (CHD). Methods A total of 122 patients with type 2 diabetes mellitus admitted to the Xiaoshan Hospital of Zhejiang from January 2017 to June 2019 were enrolled and divided into a diabetes mellitus group (54 cases) and a diabetes mellitus combined with CHD group (68 cases) according to the coronary arteriography; 50 healthy people during the same period in our hospital were selected as the healthy control group. Hemoglobin A1c (HbA1c), creatine kinase-MB (CK-MB) and cTnI were tested and compared among the three groups. The correlation between markers of myocardial injury (CK-MB, cTnI) and the degree of coronary artery disease (Gensini score) was analyzed by Pearson correlation analysis. The receiver operating characteristic (ROC) curve was used to assess the value of CK-MB and cTnI for predicting whether patients with type 2 diabetes mellitus have CHD. Results The levels of HbA1c, CK-MB and cTnI all showed significant differences among 3 groups (F = 26.820, 14.011, 93.287; all P 0.05) in the patients with type 2 diabetes mellitus and CHD. The ROC curve showed that cTnI was valuable for predicting whether patients with type 2 diabetes mellitus have CHD, and the area under the curve was 0.765. With the optimal cTnI cut-off point > 23.5 ng/L, the sensitivity and specificity were 72.1% and 70.4%, respectively. Conclusion Serum cTnI isclinically valuable for predicting whether patients with type 2 diabetes mellitus have CHD, which is often in a low level or slight increase. Key words: Troponin I; Diabetes mellitus, type 2; Coronary heart disease; Hemoglobin A1c; Creatine kinase-MB